A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate.

A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate.

Oral daily and weekly bisphosphonates represent the current mainstay of treatment for postmenopausal osteoporosis (PMO). However, the inconvenience of frequent dosing is known to negatively affect adherence to therapy in the long term. This has prompted the development of convenient oral bisphosphon...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Reginster, J, Felsenberg, D, Cooper, C, Stakkestad, J, Miller, P, Kendler, D, Adami, S, McClung, MR, Bolognese, M, Civitelli, R, Dumont, E, Bonvoisin, B, Recker, R, Delmas, P
Format:	Journal article
Język:	English
Wydane:	2006

Podobne zapisy

Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study.
od: Miller, P, i wsp.
Wydane: (2005)

Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study.
od: Reginster, J, i wsp.
Wydane: (2006)

The mobile study long-term extension: Progressive improvements in efficacy with oral ibandronate (150mg) when administered monthly
od: Reginster, J, i wsp.
Wydane: (2007)

Gastrointestinal tolerability with ibandronate after previous weekly bisphosphonate treatment
od: Richard Derman, i wsp.
Wydane: (2009-09-01)

Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data.
od: Cranney, A, i wsp.
Wydane: (2009)

Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing.
od: Bauss, F, i wsp.
Wydane: (2004)

VIBE: Evaluation of Ibandronate Efficacy - Original Investigation
od: J-Y Reginster, i wsp.
Wydane: (2008-12-01)

VIBE: Evaluation of Ibandronate Efficacy - Original Investigation
od: J-Y Reginster, i wsp.
Wydane: (2008-12-01)

The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma.
od: Shipman, C, i wsp.
Wydane: (2000)

Administration of bisphosphonate (ibandronate) impedes molar tooth movement in rabbits: A radiographic assessment
od: V Venkataramana, i wsp.
Wydane: (2014-01-01)

Ibandronate: pharmacology and preclinical studies.
od: Russell, R
Wydane: (2006)

First Indian prospective randomized comparative study evaluating adherence and compliance of postmenopausal osteoporotic patients for daily alendronate, weekly risedronate and monthly ibandronate regimens of bisphosphonates
od: Vishal R Tandon, i wsp.
Wydane: (2014-01-01)

Efficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis.
od: Cooper, C, i wsp.
Wydane: (2003)

Efficacy of generic alendronate and ibandronate in post menopausal osteoporosis
od: NP Somasundaram, i wsp.
Wydane: (2012-03-01)

Inhibitory actions by ibandronate sodium, a nitrogen-containing bisphosphonate, on calcium-activated potassium channels in Madin–Darby canine kidney cells
od: Sheng-Nan Wu, i wsp.
Wydane: (2015-01-01)

A reappraisal of generic bisphosphonates in osteoporosis.
od: Kanis, J, i wsp.
Wydane: (2012)

Intermittent intravenous ibandronate therapy for osteoporosis
od: L I Alekseeva, i wsp.
Wydane: (2008-09-01)

Rapid and sustained hip fracture risk reduction with risedronate in elderly women with osteoporosis
od: Cooper, C, i wsp.
Wydane: (2001)

Bisphosphonates in the management of postmenopausal osteoporosis – optimizing efficacy in clinical practice
od: Oliver Bock, i wsp.
Wydane: (2008-06-01)

Skeletal responses to romosozumab after 12 months of denosumab
od: Michael R. McClung, i wsp.
Wydane: (2021-07-01)

Pain control with ibandronate for bone marrow oedema of the knee
od: Livia Küchler, i wsp.
Wydane: (2020-11-01)

EFFECT OF ZOLEDRONIC AND IBANDRONIC ACIDS ON BONE METABOLISM IN WOMEN WITH POSTMENOPAUSAL OSTEOPOROSIS
od: O V Yakushevskaya, i wsp.
Wydane: (2012-08-01)

Podocyte Disease Following Treatment with Intravenous Ibandronate in an Older Patient
od: Ye Rin Chung, i wsp.
Wydane: (2024-06-01)

Efficiency of Ibandronate in Monotherapy and in Combination with Alfacalcidol in Women with Postmenopausal Osteoporosis
od: S.I. Ismailov, i wsp.
Wydane: (2016-09-01)

Combined Use of Ibandronate and Eldecalcitol in Postmenopausal Japanese Women with Osteoporosis
od: Junichi Takada, i wsp.
Wydane: (2016-12-01)

Quarterly intravenous injection of ibandronate to treat osteoporosis in postmenopausal women
od: Philip Sambrook
Wydane: (2007-04-01)

Ibandronate: The loading dose concept in the treatment of metastatic bone pain
od: Gerrit Steffen Maier, i wsp.
Wydane: (2016-03-01)

Bones, breasts, and bisphosphonates: rationale for the use of zoledronic acid in advanced and early breast cancer
od: Allan Lipton
Wydane: (2011-03-01)

Alendronate and ibandronate affect osteoclast formation and size differently from risedronate and zoledronate
od: Mabilleau, G, i wsp.
Wydane: (2011)

Treatment of patients with postmenopausal osteoporosis is worthwhile. The position of the International Osteoporosis Foundation.
od: Delmas, P, i wsp.
Wydane: (2005)

Administration of PTH and ibandronate increases ovariectomized rat compact bone viscoelasticity
od: Yang, Xiao, i wsp.
Wydane: (2013)

Case series: Chemical pneumonitis caused by exposure of sodium ibandronate powder
od: Ting Pan, i wsp.
Wydane: (2025-02-01)

Influence of ibandronate therapy on homocysteine and leptin levels in postmenopausal women with osteoporosis
od: Tat'yana Sergeevna Borodich
Wydane: (2015-12-01)

Clinical advantage and tolerability of ibandronate in hemodialysis patients: a retrospective study
od: Satoru Mitsuboshi, i wsp.
Wydane: (2018-01-01)

Predictors of Ibandronate Efficacy for the Management of Osteoporosis: A Meta-Regression Analysis.
od: Zeren Ma, i wsp.
Wydane: (2016-01-01)

Local application of ibandronate/gelatin sponge improves osteotomy healing in rabbits.
od: Zongyou Yang, i wsp.
Wydane: (2015-01-01)

Avalanche character and fatalities in the high mountains of Asia
od: D.M. McClung
Wydane: (2016-01-01)

Romosozumab for the treatment of osteoporosis
od: Michael R. McClung
Wydane: (2018-03-01)

Emerging Therapies for Osteoporosis
od: Michael R. McClung
Wydane: (2015-12-01)

Efficacy and safety of once monthly ibandronate treatment in patients with reduced bone mineral density: Esther study
od: Vujasinović-Stupar Nada, i wsp.
Wydane: (2010-01-01)